RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target
RBC Capital Reiterates Sector Perform on Incyte, Maintains $70 Price Target
Incyte Analyst Ratings
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
Johnson & Johnson Analyst Ratings
Johnson & Johnson Reports Publication Of Findings From Nipocalimab Phase 3 Study In Broad Antibody Positive Population Of People With Generalized Myasthenia Gravis In The Lancet Neurology